Senseonics (NYSE:SENS) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.

Senseonics Price Performance

Shares of Senseonics stock traded down $0.01 during trading on Friday, reaching $0.51. 1,500,591 shares of the stock traded hands, compared to its average volume of 2,443,058. Senseonics has a 52-week low of $0.38 and a 52-week high of $1.05. The company has a debt-to-equity ratio of 1.15, a current ratio of 7.53 and a quick ratio of 7.03. The firm’s fifty day moving average price is $0.53. The firm has a market cap of $268.49 million, a P/E ratio of -4.60 and a beta of 0.91.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Senseonics had a negative return on equity of 146.90% and a negative net margin of 270.13%. The company had revenue of $8.00 million during the quarter, compared to analyst estimates of $7.62 million. On average, research analysts predict that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Trading of Senseonics

Several hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after purchasing an additional 211,128 shares during the last quarter. RPO LLC purchased a new position in Senseonics during the fourth quarter worth $37,000. Ausdal Financial Partners Inc. increased its position in Senseonics by 53.2% during the third quarter. Ausdal Financial Partners Inc. now owns 72,000 shares of the company’s stock valued at $43,000 after acquiring an additional 25,000 shares during the last quarter. Finally, Cornerstone Wealth Management LLC raised its stake in shares of Senseonics by 55.9% in the third quarter. Cornerstone Wealth Management LLC now owns 55,750 shares of the company’s stock valued at $34,000 after acquiring an additional 20,000 shares during the period. 12.36% of the stock is currently owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.